KR20180077324A - 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 - Google Patents

시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 Download PDF

Info

Publication number
KR20180077324A
KR20180077324A KR1020187018487A KR20187018487A KR20180077324A KR 20180077324 A KR20180077324 A KR 20180077324A KR 1020187018487 A KR1020187018487 A KR 1020187018487A KR 20187018487 A KR20187018487 A KR 20187018487A KR 20180077324 A KR20180077324 A KR 20180077324A
Authority
KR
South Korea
Prior art keywords
formula
salt
compound
rti
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187018487A
Other languages
English (en)
Korean (ko)
Inventor
리차드 폴니아섹
스티븐 파이퍼
리차드 유
아론 쿨렌
에릭 다우디
즈엉 쩐
케네스 켄트
종신 저우
더그 코르도
레아 이스턴
Original Assignee
길리애드 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42634770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20180077324(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 길리애드 사이언시즈, 인코포레이티드 filed Critical 길리애드 사이언시즈, 인코포레이티드
Publication of KR20180077324A publication Critical patent/KR20180077324A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/70—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by reduction of unsaturated amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/34—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfuric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187018487A 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체 Ceased KR20180077324A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16649809P 2009-04-03 2009-04-03
US61/166,498 2009-04-03
PCT/US2010/029633 WO2010115000A2 (en) 2009-04-03 2010-04-01 Methods and intermediates for preparing pharmaceutical agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177009970A Division KR101874557B1 (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체

Publications (1)

Publication Number Publication Date
KR20180077324A true KR20180077324A (ko) 2018-07-06

Family

ID=42634770

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187018487A Ceased KR20180077324A (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체
KR1020177009970A Active KR101874557B1 (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체
KR1020117026120A Active KR101728375B1 (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177009970A Active KR101874557B1 (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체
KR1020117026120A Active KR101728375B1 (ko) 2009-04-03 2010-04-01 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체

Country Status (27)

Country Link
US (4) US8497396B2 (cg-RX-API-DMAC10.html)
EP (2) EP2414325B1 (cg-RX-API-DMAC10.html)
JP (8) JP5612662B2 (cg-RX-API-DMAC10.html)
KR (3) KR20180077324A (cg-RX-API-DMAC10.html)
CN (4) CN104876888B (cg-RX-API-DMAC10.html)
AP (1) AP2887A (cg-RX-API-DMAC10.html)
AR (1) AR076027A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010232559B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI1012638B8 (cg-RX-API-DMAC10.html)
CA (4) CA2925137C (cg-RX-API-DMAC10.html)
CL (1) CL2011002370A1 (cg-RX-API-DMAC10.html)
CO (1) CO6400216A2 (cg-RX-API-DMAC10.html)
EA (2) EA201590979A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP11011391A (cg-RX-API-DMAC10.html)
ES (1) ES2548252T3 (cg-RX-API-DMAC10.html)
HK (1) HK1223912A1 (cg-RX-API-DMAC10.html)
IL (4) IL215399A (cg-RX-API-DMAC10.html)
MX (2) MX2011010397A (cg-RX-API-DMAC10.html)
NZ (4) NZ617773A (cg-RX-API-DMAC10.html)
PE (1) PE20120617A1 (cg-RX-API-DMAC10.html)
PT (1) PT2414325E (cg-RX-API-DMAC10.html)
SG (2) SG174585A1 (cg-RX-API-DMAC10.html)
TW (2) TW201518283A (cg-RX-API-DMAC10.html)
UA (1) UA108738C2 (cg-RX-API-DMAC10.html)
UY (1) UY32535A (cg-RX-API-DMAC10.html)
WO (1) WO2010115000A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201107430B (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
JP2012140390A (ja) * 2011-01-06 2012-07-26 Sumitomo Chemical Co Ltd α−アミノ−γ−ブチロラクトンの製造方法
ES2543923T3 (es) * 2011-05-02 2015-08-25 Gilead Sciences, Inc. Sales sólidas amorfas de Cobicistat (GS-9350)
MX2014009344A (es) * 2012-02-03 2015-05-11 Gilead Sciences Inc Metodos e intermediarios para preparar agentes farmaceuticos.
WO2014047849A1 (zh) * 2012-09-27 2014-04-03 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
WO2014057498A2 (en) 2012-10-08 2014-04-17 Mylan Laboratories Ltd. Process for the preparation of cobicistat intermediates
WO2014105777A1 (en) * 2012-12-26 2014-07-03 Assia Chemical Industries Ltd. Cobicostat dichlohydrate salt
CN104370777A (zh) * 2013-08-13 2015-02-25 上海迪赛诺化学制药有限公司 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用
JP2016538312A (ja) * 2013-11-29 2016-12-08 マイラン ラボラトリーズ リミテッドMylan Laboratories Limited 非晶質のコビシスタットの固体分散体
EP3077373B1 (en) 2013-12-03 2018-09-12 Mylan Laboratories Ltd. Preparation of cobicistat intermediates
CN104193643B (zh) * 2014-09-12 2016-02-10 宁波九胜创新医药科技有限公司 用于合成抗艾滋病药物增强剂cobicistat的中间体
CN104447472A (zh) * 2014-11-06 2015-03-25 江苏森萱医药化工股份有限公司 D)-2-苄基-n,n-二甲基氮杂环丙烷基-1-磺酰胺合成方法
CN104557565B (zh) * 2015-01-08 2016-07-06 浙江工业大学 抗艾滋病药物增强剂Cobicistat关键中间体盐酸盐的制备方法
US10454867B2 (en) * 2015-02-09 2019-10-22 Airwatch Llc Enhanced e-mail delivery to mobile devices
US10351556B2 (en) * 2015-02-18 2019-07-16 Msn Laboratories Private Limited Process for the preparation of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2s)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4YL] methyl} carbamoyl) amino]-4-(morpholin-4-yl)butanoyl]amino)-1,6-diphenylhexan-2-yl]carbamate
CN107674039A (zh) * 2016-08-01 2018-02-09 上海朴颐化学科技有限公司 一种可比西他中间体的制备方法
US20180085387A1 (en) 2016-09-27 2018-03-29 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
CN109912530A (zh) * 2017-12-13 2019-06-21 上海奥博生物医药技术有限公司 一种可比司他原料杂质的制备方法
CN109232301B (zh) * 2018-10-15 2021-01-01 天津希恩思生化科技有限公司 一种四异丙基肼的制备方法
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
CN110878071A (zh) * 2019-11-21 2020-03-13 华南农业大学 一种α-氨基-γ-丁内酯及其盐的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1183026E (pt) * 1999-06-04 2006-11-30 Abbott Lab Formulações farmacêuticas melhoradas incluindo ritonavir
US20030153771A1 (en) 2001-09-27 2003-08-14 Kolb Hartmuth C. Large scale synthesis of optically pure aziridines
WO2003106445A1 (en) * 2002-06-12 2003-12-24 Qsi Pharma A/S Compounds and methods for controlling bacterial virulence
EP1771536A1 (en) * 2004-07-23 2007-04-11 The Procter and Gamble Company Liquid detergent composition for improved low temperature grease cleaning and starch soil cleaning
US7786153B2 (en) * 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
KR101477822B1 (ko) * 2006-07-07 2015-01-02 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
PT3150586T (pt) * 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
KR20100040896A (ko) * 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
PT2231628E (pt) * 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Also Published As

Publication number Publication date
JP6491706B2 (ja) 2019-03-27
NZ708978A (en) 2017-01-27
US9428473B2 (en) 2016-08-30
HK1223912A1 (en) 2017-08-11
TWI464165B (zh) 2014-12-11
MX338731B (es) 2016-04-28
IL237643A (en) 2017-01-31
ECSP11011391A (es) 2012-03-30
TW201518283A (zh) 2015-05-16
IL237642A0 (en) 2015-04-30
JP2020189861A (ja) 2020-11-26
IL250068A0 (en) 2017-03-30
WO2010115000A3 (en) 2011-09-22
EA201590979A1 (ru) 2016-02-29
CA3083433A1 (en) 2010-10-07
KR20120006035A (ko) 2012-01-17
ES2548252T3 (es) 2015-10-15
US8497396B2 (en) 2013-07-30
AU2010232559B2 (en) 2015-06-18
US20140088304A1 (en) 2014-03-27
CN104876888B (zh) 2018-06-15
CL2011002370A1 (es) 2012-05-25
CA2925137C (en) 2018-07-31
US8853210B2 (en) 2014-10-07
JP2018162274A (ja) 2018-10-18
HK1214265A1 (zh) 2016-07-22
JP6336161B2 (ja) 2018-06-06
EA201190179A1 (ru) 2013-01-30
PE20120617A1 (es) 2012-05-26
CN111217808A (zh) 2020-06-02
US20100256366A1 (en) 2010-10-07
SG174585A1 (en) 2011-10-28
EP2414325B1 (en) 2015-08-26
US20150005493A1 (en) 2015-01-01
CN102438982A (zh) 2012-05-02
US20160002186A1 (en) 2016-01-07
NZ594864A (en) 2014-03-28
ZA201107430B (en) 2012-12-27
WO2010115000A2 (en) 2010-10-07
AU2010232559A1 (en) 2011-10-06
NZ726536A (en) 2018-04-27
CA2925137A1 (en) 2010-10-07
EP2414325A2 (en) 2012-02-08
NZ617773A (en) 2016-02-26
CA2754698C (en) 2016-06-07
IL237643A0 (en) 2015-04-30
BRPI1012638B8 (pt) 2021-05-25
JP6180561B2 (ja) 2017-08-16
CA2754698A1 (en) 2010-10-07
CN107382997A (zh) 2017-11-24
SG10201404926UA (en) 2015-02-27
BRPI1012638A2 (pt) 2016-04-05
AP2011005864A0 (en) 2011-10-31
JP2014193897A (ja) 2014-10-09
TW201100412A (en) 2011-01-01
KR20170043672A (ko) 2017-04-21
CA3008903A1 (en) 2010-10-07
JP5986599B2 (ja) 2016-09-06
UA108738C2 (uk) 2015-06-10
UY32535A (es) 2010-10-29
EP3009434A1 (en) 2016-04-20
JP2023002679A (ja) 2023-01-10
MX2011010397A (es) 2011-10-24
CA3008903C (en) 2021-06-08
HK1166976A1 (zh) 2012-11-16
CN107382997B (zh) 2021-02-26
JP2017122107A (ja) 2017-07-13
CO6400216A2 (es) 2012-03-15
KR101874557B1 (ko) 2018-07-04
KR101728375B1 (ko) 2017-04-19
PT2414325E (pt) 2015-10-29
IL215399A0 (en) 2011-12-29
IL215399A (en) 2015-11-30
CN104876888A (zh) 2015-09-02
JP5612662B2 (ja) 2014-10-22
US9115100B2 (en) 2015-08-25
AU2010232559A8 (en) 2011-11-10
AR076027A1 (es) 2011-05-11
JP2012522797A (ja) 2012-09-27
HK1245785A1 (zh) 2018-08-31
CN102438982B (zh) 2015-05-06
JP2018008983A (ja) 2018-01-18
IL237642A (en) 2017-01-31
JP2016128476A (ja) 2016-07-14
BRPI1012638B1 (pt) 2021-04-20
AP2887A (en) 2014-05-31
CA3083433C (en) 2022-08-09
EA022739B1 (ru) 2016-02-29

Similar Documents

Publication Publication Date Title
KR101874557B1 (ko) 시토크롬 p450 모노옥시게나아제 억제제의 제조 방법 및 관련 중간체
HK1166976B (en) Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved
HK40022057A (en) Method and intermediates for preparing pharmaceutical agents
EA016854B1 (ru) Новый способ получения эфира 3-амино-5-фтор-4-диалкоксипентановой кислоты
HK1245785B (en) Methods and intermediates for preparing pharmaceutical agents

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180628

Application number text: 1020177009970

Filing date: 20170412

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180727

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180813

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181017

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180813

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I